Literature DB >> 24883006

Sofosbuvir: a new oral once-daily agent for the treatment of hepatitis C virus infection.

Agnes Cha, Aliaksandr Budovich.   

Abstract

Sofosbuvir: A new oral oncedaily agent for the treatment of hepatitis C virus infection.

Entities:  

Year:  2014        PMID： 24883006      PMCID： PMC4029125     

Source DB:  PubMed          Journal:  P T        ISSN： 1052-1372


  22 in total

Review 1.  The role of resistance in HCV treatment.

Authors:  Johannes Vermehren; Christoph Sarrazin
Journal:  Best Pract Res Clin Gastroenterol       Date:  2012-08       Impact factor: 3.043

2.  Sticker shock and the price of new therapies for hepatitis C: is it worth it?

Authors:  Nancy S Reau; Donald M Jensen
Journal:  Hepatology       Date:  2014-03-01       Impact factor: 17.425

Review 3.  Hepatitis C virus infection in USA: an estimate of true prevalence.

Authors:  Eric Chak; Andrew H Talal; Kenneth E Sherman; Eugene R Schiff; Sammy Saab
Journal:  Liver Int       Date:  2011-03-16       Impact factor: 5.828

4.  Dynamic hepatitis C virus genotypic and phenotypic changes in patients treated with the protease inhibitor telaprevir.

Authors:  Christoph Sarrazin; Tara L Kieffer; Doug Bartels; Brian Hanzelka; Ute Müh; Martin Welker; Dennis Wincheringer; Yi Zhou; Hui-May Chu; Chao Lin; Christine Weegink; Henk Reesink; Stefan Zeuzem; Ann D Kwong
Journal:  Gastroenterology       Date:  2007-02-21       Impact factor: 22.682

5.  Sofosbuvir for previously untreated chronic hepatitis C infection.

Authors:  Eric Lawitz; Alessandra Mangia; David Wyles; Maribel Rodriguez-Torres; Tarek Hassanein; Stuart C Gordon; Michael Schultz; Mitchell N Davis; Zeid Kayali; K Rajender Reddy; Ira M Jacobson; Kris V Kowdley; Lisa Nyberg; G Mani Subramanian; Robert H Hyland; Sarah Arterburn; Deyuan Jiang; John McNally; Diana Brainard; William T Symonds; John G McHutchison; Aasim M Sheikh; Zobair Younossi; Edward J Gane
Journal:  N Engl J Med       Date:  2013-04-23       Impact factor: 91.245

6.  Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment options.

Authors:  Ira M Jacobson; Stuart C Gordon; Kris V Kowdley; Eric M Yoshida; Maribel Rodriguez-Torres; Mark S Sulkowski; Mitchell L Shiffman; Eric Lawitz; Gregory Everson; Michael Bennett; Eugene Schiff; M Tarek Al-Assi; G Mani Subramanian; Di An; Ming Lin; John McNally; Diana Brainard; William T Symonds; John G McHutchison; Keyur Patel; Jordan Feld; Stephen Pianko; David R Nelson
Journal:  N Engl J Med       Date:  2013-04-23       Impact factor: 91.245

7.  Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group.

Authors:  J G McHutchison; S C Gordon; E R Schiff; M L Shiffman; W M Lee; V K Rustgi; Z D Goodman; M H Ling; S Cort; J K Albrecht
Journal:  N Engl J Med       Date:  1998-11-19       Impact factor: 91.245

8.  Biochemical properties of hepatitis C virus NS5B RNA-dependent RNA polymerase and identification of amino acid sequence motifs essential for enzymatic activity.

Authors:  V Lohmann; F Körner; U Herian; R Bartenschlager
Journal:  J Virol       Date:  1997-11       Impact factor: 5.103

Review 9.  Perspectives and challenges of interferon-free therapy for chronic hepatitis C.

Authors:  Christian M Lange; Stefan Zeuzem
Journal:  J Hepatol       Date:  2012-10-24       Impact factor: 25.083

10.  Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection.

Authors:  Nezam Afdhal; K Rajender Reddy; David R Nelson; Eric Lawitz; Stuart C Gordon; Eugene Schiff; Ronald Nahass; Reem Ghalib; Norman Gitlin; Robert Herring; Jacob Lalezari; Ziad H Younes; Paul J Pockros; Adrian M Di Bisceglie; Sanjeev Arora; G Mani Subramanian; Yanni Zhu; Hadas Dvory-Sobol; Jenny C Yang; Phillip S Pang; William T Symonds; John G McHutchison; Andrew J Muir; Mark Sulkowski; Paul Kwo
Journal:  N Engl J Med       Date:  2014-04-11       Impact factor: 91.245
View more
  7 in total

Review 1.  Current status and emerging challenges in the treatment of hepatitis C virus genotypes 4 to 6.

Authors:  Vasilios Papastergiou; Stylianos Karatapanis
Journal:  World J Clin Cases       Date:  2015-03-16       Impact factor: 1.337

2.  Effect of Sofosbuvir/Ledipasvir and Glecaprevir/Pibrentasvir on Serum Creatinine.

Authors:  Waseem Amjad; Talan Zhang; Anurag Maheshwari; Paul J Thuluvath
Journal:  J Clin Exp Hepatol       Date:  2021-08-20

3.  Efficacy and safety of sofosbuvir-ledipasvir for treatment of a cohort of Egyptian patients with chronic hepatitis C genotype 4 infection.

Authors:  Ossama A Ahmed; Hany H Kaisar; Rehab Badawi; Nehad Hawash; Hossam Samir; Sherif St Shabana; Mohamed Hassan A Fouad; Fatma H Rizk; Samy A Khodeir; Sherief Abd-Elsalam
Journal:  Infect Drug Resist       Date:  2018-03-01       Impact factor: 4.003

Review 4.  Phosphoramidates and phosphonamidates (ProTides) with antiviral activity.

Authors:  Magdalena Slusarczyk; Michaela Serpi; Fabrizio Pertusati
Journal:  Antivir Chem Chemother       Date:  2018 Jan-Dec

5.  Analysis of the Enzymatic Activity of an NS3 Helicase Genotype 3a Variant Sequence Obtained from a Relapse Patient.

Authors:  Paola J S Provazzi; Sourav Mukherjee; Alicia M Hanson; Mauricio L Nogueira; Bruno M Carneiro; David N Frick; Paula Rahal
Journal:  PLoS One       Date:  2015-12-10       Impact factor: 3.240

Review 6.  Tackling HCV-3 in Asia: Breakthroughs for Efficient and Cost-effective Treatment Strategies.

Authors:  Naba Saeed; Ahmet Gurakar
Journal:  Euroasian J Hepatogastroenterol       Date:  2016-07-09

7.  Host phosphatidic acid phosphatase lipin1 is rate limiting for functional hepatitis C virus replicase complex formation.

Authors:  Lidia Mingorance; Victoria Castro; Ginés Ávila-Pérez; Gema Calvo; María Josefa Rodriguez; José L Carrascosa; Sofía Pérez-Del-Pulgar; Xavier Forns; Pablo Gastaminza
Journal:  PLoS Pathog       Date:  2018-09-18       Impact factor: 6.823
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.